NCT01635712 2017-04-26Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological MalignanciesEsanex Inc.Phase 1 Completed10 enrolled
NCT00595686 2012-05-17Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological MalignanciesEsanex Inc.Phase 1 Completed25 enrolled